UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Glioblastoma (grade IV)
This single-center Phase I/Ib study in recurrent glioblastoma (GBM) aims to establish a recommended phase 2 dose of the mTOR inhibitor RMC-552 in GBM participants as well as to evaluate safety and antitumor effect of this drug.
Conditions
Glioblastoma (grade IV)
Glioma
This is randomized multi-site phase II clinical trial that aims to assess whether a ketogenic diet improves overall survival in newly diagnosed glioblastoma patients who receive standard of care treatment when compared to the standard anti-cancer diet.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
This phase I/IIa study in patients with recurrent IDH-mutant glioma will investigate the safety and preliminary efficacy of AZD9574 in combination with temozolomide.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Glioblastoma (grade IV)
Astrocytoma
Oligodendroglioma
This is an international, open-label phase II clinical trial for recurrent patients who have a glioma harboring a BRAF abnormality.
Conditions
Glioma
Glioblastoma (grade IV)
This phase II/III clinical trial is a response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.
Conditions
Meningioma
This single center pilot trial is designed to demonstrate the safety of adjuvant hypofractionated stereotactic radiosurgery for patients after gross total of resection of intermediate risk meningioma.
Conditions
Glioma
Glioblastoma (grade IV)
This is a first-in-human phase I study to assess the safety and feasibility of using an IV infusion of E-SYNC T cells to treat patients with EGFRvIII-mutated glioblastoma (GBM).
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in patients with newly diagnosed high grade glioma.